Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials

By sjmartinez • April 11, 2025

Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J, Meng X, Luo Y, Chen Z, Wang W, Yi T, Li Y, Yin Y, Xu H, Yu G, Mi Y, Fan Y, Wainberg ZA, Wang X, Su C, Yu Q, Lai S, Sun L, Zhuang W, Wang X, Yang J, Li Y, Ge J, Li J, Zhang L, Fang W. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials. Nat Med. 2025 Apr 10. doi: 10.1038/s41591-025-03638-2. Epub ahead of print. PMID: 40210967.

Tags: Hematology/Oncology, Publications

Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy

Carlson SG, Puliafito BR, Kawai K, Senaratne TN, Lee TD, Lin T, Timmerman J, Larson SM. Impact of clonal hematopoiesis of indeterminate potential on treatment[...]

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

Owen RG, McCarthy H, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Cheson[...]

Exploring Features of the Parasport Environment Associated With Quality Participation

Gee CM, Evans MB, Sinden AR, Shirazipour CH, Martin Ginis KA, Latimer-Cheung AE. Exploring Features of the Parasport Environment Associated With Quality Participation. Adapt Phys[...]